Understanding pharmacokinetics to improve tuberculosis treatment outcome.
about
Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status ConsiderationsThe Influence of Mining and Human Immunodeficiency Virus Infection Among Patients Admitted for Retreatment of Tuberculosis in Northern Tanzania.Prevalence of Tuberculosis, Drug Susceptibility Testing, and Genotyping of Mycobacterial Isolates from Pulmonary Tuberculosis Patients in Dessie, EthiopiaNaïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis.Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.The challenges of pharmacokinetic variability of first-line anti-TB drugs.A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV+ Population is not Related to Anti-retroviral Therapy.Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics.Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer.Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?Strain Diversity and the Evolution of Antibiotic Resistance.Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial
P2860
Q28079207-3C8D34EF-885D-4E39-948D-D99412DB128DQ30279294-4E959960-4EED-4006-8CEB-965D9DD9BD76Q35769140-85843591-13BC-4004-AC80-EFD911C1859CQ35978007-E29B3289-4C98-4B1A-AC37-A8C8CCCE093BQ38865905-13A03131-37F0-495E-82A3-8F89C6986B81Q38977166-2AED0CAA-6345-44C2-AFB6-0060D6511194Q39456569-067E9794-48CF-4B1C-B0C5-2F4771A313CFQ39539828-E6AA9563-D604-4764-8B32-BD7EC7422650Q40180361-1C1D79B9-5865-4824-9C70-89E5F695CCC8Q41514180-6F5E29AA-FF9C-4953-9DD3-5822326C72CCQ42281128-A2E37035-1F9E-454B-8597-CE6A926F97ACQ47332682-703A4378-E849-4626-AFC2-D134E9DCBBF1Q47851713-90DB0C2B-2290-46CD-9EF7-932CFDDD2532Q53698038-252A97E7-B10A-4F73-99E2-A1055F88FE08Q57276328-A7A9A2A1-5910-4B24-89C8-7F628C74057F
P2860
Understanding pharmacokinetics to improve tuberculosis treatment outcome.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Understanding pharmacokinetics to improve tuberculosis treatment outcome.
@ast
Understanding pharmacokinetics to improve tuberculosis treatment outcome.
@en
type
label
Understanding pharmacokinetics to improve tuberculosis treatment outcome.
@ast
Understanding pharmacokinetics to improve tuberculosis treatment outcome.
@en
altLabel
Understanding pharmacokinetics to improve tuberculosis treatment outcome
@en
prefLabel
Understanding pharmacokinetics to improve tuberculosis treatment outcome.
@ast
Understanding pharmacokinetics to improve tuberculosis treatment outcome.
@en
P2860
P921
P1476
Understanding pharmacokinetics to improve tuberculosis treatment outcome.
@en
P2093
Jonathan Reynolds
Scott K Heysell
P2860
P304
P356
10.1517/17425255.2014.895813
P407
P577
2014-03-06T00:00:00Z